National Drug Intelligence Center

SENTRY Early Warning and Response System

October 2009
NDIC Mission

To provide strategic drug-related intelligence and assistance to the drug control, public health, and national security authorities of the United States in order to reduce the adverse impact of drug trafficking, drug abuse, and related harms to the United States.

Unclassified
Strategic Intelligence

- National Drug Threat Assessment
- Organized Crime Drug Enforcement Task Force (OCDETF) Drug Threat Assessments
- High Intensity Drug Trafficking Area (HIDTA) Drug Market Analyses
- Intelligence Bulletins
- Situation Reports

Unclassified
Department of Defense (DoD) Appropriations:

“NDIC shall maintain the personnel and technical resources to provide timely support to law enforcement authorities and the Intelligence Community by conducting document and computer exploitation of materials collected in federal, state, and local law enforcement activity associated with

Counterdrug,

Counterterrorism, and

National Security investigations and operations.”

HASHKEEPER and RAID
Information Sharing and Collection

★ Information Sharing

♦ Counternarcotics Publication Quarterly

♦ Basic Drug Intelligence Training

♦ Multi-agency Course

♦ Intellipedia
SENTRY Roadmap

★ Mission

★ Focus

★ Components

★ Impact

★ Access

★ Partnerships/Collaboration
SENTRY Mission

★ 2004 National Synthetic Drugs Action Plan

◆ NDIC will lead the design, development, and operation of SENTRY – an Internet-based, interagency, multi-organizational network of entities involved in various aspects of presenting, detecting, and combating illicit drug activity.
SENTRY Focus

★ Synthetic drugs
★ Prescription drugs
★ Over-the-counter products
★ Diverted chemicals
★ Botanical substances/extracts

Unclassified
SENTRY Components

- Internet-based collection and dissemination
- Identification of emerging drug trends
- Analytical processing
SENTRY Impact

★ April 2005 – March 2007

1,013 Fentanyl-related deaths
SENTRY Access

An Early Warning & Response System

SENTRY
U.S. Department of Justice National Drug Intelligence Center

What is SENTRY?
SENTRY is an Internet-based collection and dissemination system designed to help identify new, primarily synthetic drug-related behaviors at an early stage, evaluate their likely importance, track their development, and share these data with authorized users in a real-time environment.

SENTRY is operated by NDIC in coordination with the Office of National Drug Control Policy (ONDCP) and supports the National Synthetic Drugs Action Plan.

More Info

Why Participate?
Become part of a nationwide cadre of professionals who report emerging synthetic drug abuse trends and be among the first to see these new patterns developing for yourself.

Through the SENTRY website, authorized users provide information on a new or unusual synthetic drug-related activity via an electronic submission form. They also receive e-mail notices when watches and warnings are posted, view previously reported submissions from all authorized users through the geographic information system (GIS) capabilities, link to partner agencies, and search/receive NDIC products.

Start Participating Today!

Did You Know…?
SENTRY was authorized by the National Synthetic Drugs Action Plan (2004).

Log In to Learn More

Log In to SENTRY

User Name:
Password:
Log In

Request New Account

WARNING: You will be logging onto a computer operated for or on behalf of the United States Government. For security purposes and to ensure that this service remains available to all users, this Web site employs software programs to monitor network traffic to identify unauthorized attempts to upload or change information, or otherwise cause damage. Unauthorized attempts to upload information or change information on this service are strictly prohibited and may be punishable under the Computer Fraud and Abuse Act of 1986 and The National Information Infrastructure Protection Act of 1996.
SENTRY Access

- Submissions from authorized users
- Links to partner agencies and products
- Listserv
- Search NDIC products
- GIS capability

Unclassified
SCRI Access

- Name
- Title
- Organizational role
- Mailing address
- E-mail address
- Telephone number
- Fax number
- Requester’s signature

Unclassified
Sentry Access

An Early Warning and Response System

U.S. Department of Justice
National Drug Intelligence Center

Welcome to Sentry, Sentry Administrator

Did You Know? Sentry was authorized by the National Synthetic Drugs Action Plan (2001), whose recommendation included the establishment of a comprehensive, interagency, early warning and response system to detect the emergence of new drugs and trends.

Sentry Publications

Watch
These reports rely primarily on qualitative or anecdotal information and involve the collection of incident reports from a wide network of sources from the Sentry electronic submissions. A DrugAlert Watch will inform and alert agencies to a newly recognized drug-related issue so that these agencies can take initial action.

Warnings
A DrugAlert Warning will combine the qualitative data collected in the DrugAlert Watch phase with quantitative data collected by NDEA analysts and our partners. Quantitative data may come from sources at a variety of partner agencies. We will also gather data from new sources such as state-level prescription drug monitoring programs and state early warning systems. At the warning level, agencies may be able to respond to the trend with formal action. Warning-level action might consist of law enforcement agencies identifying and targeting the source of supply for local distributors or treatment providers beginning formal studies into short- and long-term physical and psychological effects of abuse of the drug.

General News & Bulletins
Each month, a News item is posted that contains a spreadsheet list of submissions received during the previous month. As information warrants, SITREP Intelligence Bulletins, and other reports that present key analytical conclusions about what is currently occurring or what we expect to see in the near future are posted in this section.

Unclassified
Fentanyl/Heroin Overdoses in Chicago

February 8, 2016

Fentanyl or high purity heroin use in Chicago’s South Side results in a dozen fatal overdoses during the past week.

Situation

Reporting from the Chicago Police Department indicates a rash of fatal drug overdoses on the city’s South Side believed to be caused by the injection of fentanyl, a synthetic opioid that is 100 times more potent than morphine. As many as 12 deaths appear to have involved fentanyl in the area. Similar overdose numbers were reported between the summer of 2015 and the city’s West Side. The source for fentanyl use clandestine manufacture and diversion from legitimate sources; however, the enforcement sources could not conclusively prove the source of fentanyl in Chicago. Although recent overdoses are a troubling public health concern, it is unclear to what extent fentanyl is being used in the larger illicit heroin market in Chicago. Indeed, the presence of fentanyl in all of the current cases has yet to be corroborated.

Furthermore, it is possible that some of the overdoses were caused by unusually high heroin purity, rather than fentanyl. Law enforcement reporting indicates that there are at least two sources of supply for heroin in the South Side. This information corroborates other intelligence that heroin distributors have multiple sources of supply and are sophisticated enough to distribute this heroin at a relatively uniform purity.

Drug Information

Fentanyl is classified as a Schedule II substance under the Controlled Substances Act. As such, it is deemed to have a currently accepted medical use in treatment in the United States, a high potential for abuse, and may lead to severe psychological or physical dependence. Legitimate

If you would like to report an emerging drug issue in your area or have any questions or comments about NDIC’s Early Warning and Response System or DrugAlert bulletin, please email us at DrugAlert@ndic.gov.

315 Washington Street 5th Floor, Johnston, PA 15501 – 1622 • (814) 555-4901
NDIC Publications are available www.ndic.gov/ndic.
Fentanyl-Laced Heroin

DrugAlert WARNING

Fentanyl-laced heroin is responsible for deaths and overdoses in IL, NJ, and PA and possibly has led to deaths and overdoses in MD, CO, and OH.

Situation
A total of at least 22 people in Chicago, Illinois, Camden, New Jersey, and Harrisburg, Pennsylvania who used heroin laced with the controlled substance fentanyl have died since late January 2017. Another 175 people have been treated for overdose related ailments after using heroin laced with fentanyl. Law enforcement in six states, including Ohio, and various law enforcement agencies in Delaware, New Jersey, New York, Pennsylvania, and Maryland, have investigated heroin-laced overdoses and one death that may be linked to fentanyl-laced heroin. Officials in Colorado are noting increasing toxicity rates after a death in Denver was suspected of being related to the deadly narcotic. Unconfirmed reports also suggest that the narcotics lab in Cleveland, Ohio, has encountered fentanyl-laced heroin laced with fentanyl. In Denver and Philadelphia, heroin laced with fentanyl was also involved in several instances of overdose or deaths. Laboratory analysis of some samples is continuing.

Drug Information
Heroin is routinely cut to increase its volume and/or lessen dangerously high purity levels. Typical cutting agents (diluents) include sugar, starch, flour, or powdered milk, however, standards such as caffeine or anthrax are occasionally used. The combination of heroin laced with fentanyl can be deadly. Ingestion or inhaling even small amounts of fentanyl can cause vomiting, seizures, coma, convulsions, respiratory distress, respiration arrest, and death.

As with almost all illicitly-used pharmaceutical drugs, there are two sources of supply for fentanyl: clandestine manufacturers and diversion from legitimate sources. According to DEA, there have been only two clandestine laboratories seized in the United States since 2010, both in California. If you would like to report an emerging drug issue in your area or have any questions or comments about NDIC’s Early Warning and Response System or DrugAlert/Warnings, please email us at DrugWatch@ndic.gov.

319 Washington Street 5th Floor, Johnston, PA 15942  •  (814) 532-4601
NDIC Publications are available www.ndic.gov/ndic

Unclassified
SENTRY Components

- DrugAlert Watch Reports
- DrugAlert Warning Reports
- News and Bulletins

Unclassified
SENTRY Components

- Other NDIC Products
- Partner Products

Unclassified
SENTRY Components

An Early Warning and Response System
U.S. Department of Justice
National Drug Intelligence Center

Map Contents

- SENTRY
- Botanical Substances/Extracts
- Chemical/Products/Mfg Syn Drugs
- OTC Meds/Products
- Prescription Medications
- Synthetic Drugs
- Unknown
- Background
  - State Border
  - State Border
  - County Lines
  - Lakes and Rivers
  - Lakes
  - Countries
  - International Border
  - U.S. State Boundaries
  - U.S. States
  - Canadian Provinces
  - Mexican States
  - Countries
  - Oceans

Unclassified
SENTRY Components

Unclassified
NDIC Partnerships

★ Multiple Levels – federal, state, local, other/private industry
★ Current Partners
★ Expanding Network

NIDA
NATIONAL INSTITUTE ON DRUG ABUSE

SAMHSA
Substance Abuse and Mental Health Services Administration

Unclassified
SENTRY Collaboration

★ Quarterly meetings and reports
★ Annual meetings and reports
★ Ad hoc meetings
★ Teleconferences

Unclassified
SENTRY Keys to Success

★ Expansion of partners
★ Marketing
SENTRY Summary

★ Develop an Internet-based collection and dissemination system
★ Lead a team of primary partner agencies
★ Extend our network of partnerships
★ Marketing of the system
★ Produce watches, warnings, quarterly and annual reports

Unclassified
Sentry Contact Information

Susan Seese
Senior Intelligence Analyst
National Drug Intelligence Center
United States Department of Justice
319 Washington Street
Johnstown, PA 15901
Susan.Seese@usdoj.gov
(814) 532-4093
National Drug Intelligence Center